The world’s population is ageing. In Europe alone, the elderly population over age 65 will double from 88 to 153 million and the fastest growing segment of the population will be those over 80, tripling in number from 24 to 60 million in 2060. Low birth rates and increasing longevity are the key fac...
October 26, 2016
Journal:
Int J Epidemiol.
Author:
Neergaard JS, Dragsbæk K, Kehlet SN, Hansen HB, Hansen G, Byrjalsen I, Alexandersen P, Lindgren LM, Bihlet AR, Riis BJ, Andersen JR, Qvist P
IMPORTANCE: Additional therapies are needed for prevention of osteoporotic fractures. Abaloparatide is a selective activator of the parathyroid hormone type 1 receptor. OBJECTIVE: To determine the efficacy and safety of abaloparatide, 80 μg, vs placebo for prevention of new vertebral fracture in po...
August 16, 2016
Journal:
JAMA.
Author:
Miller PD, Hattersley G, Riis BJ, Williams GC, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C, Lau EM
Acute myocardial infarction (AMI) is often underdiagnosed in women. It is therefore of interest to identify biomarkers that indicate increased risk of AMI and thereby help clinicians to have additional focus on the difficult AMI diagnosis. Type I Collagen, a component of the cardiac extracellular ma...
April 30, 2015
Journal:
EBioMedicine
Author:
Dragsbæk K, Neergaard JS, Hansen HB, Byrjalsen I, Alexandersen P, Kehlet SN, Bay-Jensen AC, Christiansen C, Karsdal MA
Background/purpose: The aim of this study was to identify key characteristics of disease progression through investigation of the association of radiographic progression over two years with baseline Joint Space Width (JSW), Kellgren-Lawrence (KL) grade, Western Ontario and McMaster Universities Arth...
April 1, 2015
Journal:
Osteoarthritis Cartilage
Author:
Karsdal MA, Bihlet AR, Byrjalsen I, Alexandersen P, Ladel C, Andersen JR, Riis BJ, Kraus VB, Bay-Jensen AC, Christiansen C, Michaelis M
Purpose: To evaluate the structure-modifying and symptom efficacy, as well as safety and tolerability of oral salmon calcitonin (sCT) formulated with a 5-CNAC carrier (a molecule based on Eligen(®) technology), in osteoarthritis (OA) patients with moderate to severe knee pain and joint structural da...
January 1, 2015
Journal:
Osteoarthritis Cartilage
Author:
Karsdal MA, Byrjalsen I, Alexandersen P, Bihlet AR, Andersen JR, Riis BJ, Bay-Jensen AC, Christiansen C
Abstract Objective: Joint health is affected by local and systemic hormones. It is well accepted that systemic factors regulate the metabolism of joint tissues, and that substantial cross-talk between tissues actively contributes to homeostasis. In the current review, we try to define a subtype o...
May 20, 2013
Journal:
Menopause
Author:
Bay-Jensen AC, Chen-An P, Alexandersen P, Qvist P, Christiansen C, Meulenbelt I, Karsdal MA, Slagboom PE
Objective: The objective of this post hoc analysis was to investigate the effect of strontium ranelate on a cartilage degradation marker in postmenopausal women who participated in a randomized, placebo-controlled osteoporosis study. Women were stratified according to reported symptoms of osteoarthr...
For decades, hormone-replacement therapy (HRT) was considered safe and was the first choice in prevention of postmenopausal osteoporosis induced by estrogen deficiency. Numerous experimental and epidemiological studies further supported a protective effect of exogenous female sex hormones on atherog...
OBJECTIVE:Osteoarthritis (OA) is the most common form of arthritic disease, and it is a major cause of disability and impaired quality of life in the elderly. OA is a complex disease of the entire joint, including bone and cartilage, thereby presenting alternative approaches for treatment. This revi...
June 16, 2008
Journal:
Osteoarthritis Cartilage
Author:
Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, Altman RD, Christiansen C
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.